Grundläggande statistik
| CIK | 1537274 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Greenwind Holdings Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| April 19, 2017 |
newg1512g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-178741 GREENWIND HOLDINGS INC. (formerly NewGen BioPharma C |
|
| April 5, 2017 |
pdfproof.pdf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 333-178741 81-5332421 (State or other jurisdiction of incorporation) ( |
|
| March 29, 2017 |
newg8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 81-5332421 (State or other jurisdiction of incorporation) (C |
|
| March 29, 2017 |
EX-17.1 2 newgex171.htm LETTER OF RESIGNATION EXHIBIT 17.1 March 28, 2017 NewGen BioPharma Corp. Attn: Bradford Long Re: Resignation from the Board Brad, It is with great disappointment that I submit my resignation from the Board of Directors of the publicly traded Nevada Corporation, NewGen BioPharma Corp. We have all worked very hard to get the merger completed on time but given today’s action b |
|
| March 9, 2017 |
GRWD / Greenwind Nrg, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 newg10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000 |
|
| March 9, 2017 |
EXHIBIT 10.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGIS |
|
| March 9, 2017 |
Form of Securities Purchase Agreement. EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT (Signature Page) NEWGEN BIOPHARMA CORP. 506 2ND AVENUE, SUITE 1400 SEATTLE, WA 98104 Ladies & Gentlemen: The undersigned (the “Investor”), hereby confirms its agreement with you as follows: 1. This Securities Purchase Agreement, including the Terms and Conditions set forth in Annex I (the “Terms and Conditions”), the Risk Factors set forth in Annex II (th |
|
| February 27, 2017 |
newgex101.htm EXHIBIT 10.1 Date of Grant: February 23, 2017 NEWGEN BIOPHARMA CORP. RESTRICTED STOCK AWARD AGREEMENT THIS RESTRICTED STOCK AWARD AGREEMENT (this ?Agreement?) is made effective as of February 23, 2017, by and between NewGen BioPharma Corp., a Nevada corporation (the ?Company?) and Navdeep Jaikaria (?Director?). RECITALS WHEREAS, on January 10, 2017, the Company entered into an Agreem |
|
| February 27, 2017 |
newg8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 23, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 81-5332421 (State or other jurisdiction of incorporation) |
|
| February 17, 2017 |
EX-16.1 2 newgenex161.htm LETTER OF KLJ & ASSOCIATES, LLP. EXHIBIT 16.1 February 16, 2017 Securities and Exchange Commission 450 Fifth Street N.W. Washington, DC 20549 We have read the statements of NewGen BioPharma Corp., pertaining to our firm included under Item 4.01 of Form 8-K dated February 15, 2017 and agree with such statements as they pertain to our firm. Sincerely, /s/ KLJ & Associates, |
|
| February 17, 2017 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant newgen8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 15, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 81-5332421 (State or other jurisdiction of incorporatio |
|
| February 14, 2017 |
8-K 1 newgen8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 10, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 81-5332421 (State or other jurisdiction |
|
| February 14, 2017 |
2017 Equity Incentive Plan of NewGen BioPharma Corp. newgenex101.htm EXHIBIT 10.1 2017 EQUITY INCENTIVE PLAN OF NEWGEN BIOPHARMA CORP. 1. PURPOSES OF THE PLAN The purposes of the 2017 Equity Incentive Plan (?Plan?) of NEWGEN BIOPHARMA CORP., a Nevada corporation (the ?Company?), are to: 1.1 Encourage selected employees, directors, consultants and advisers to improve operations and increase the profitability of the Company; 1.2 Encourage selected emp |
|
| February 14, 2017 |
newgenex991.htm EXHIBIT 99.1 INFORMATION STATEMENT (INTENDED TO BE DISTRIBUTED TO STOCKHOLDERS ON OR ABOUT FEBRUARY 13, 2017) NEWGEN BIOPHARMA CORP. 506 2nd Avenue, Suite 1400 Seattle, Washington 98104 855-624-4793 Notice of Stockholder Action by Written Consent February 13, 2017 Dear Stockholder: The purpose of this Information Statement is to inform the holders of record, as of the close of busi |
|
| February 9, 2017 |
8-K 1 newgen8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 8, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incor |
|
| February 2, 2017 |
Changes in Control of Registrant newgen8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 30, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incorporation) (Comm |
|
| January 26, 2017 |
newgen8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 26, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incorporation) (Comm |
|
| January 25, 2017 |
NewGen BioPharma FORM 10-K (Annual Report) newgen10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended October 31, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-1537274 NEWGEN BIOPHARMA CORP. (Name of registrant as specified in it |
|
| January 25, 2017 |
newgenex31.htm EXHIBIT 3.1 1 2 3 4 5 6 7 8 9 10 |
|
| January 25, 2017 |
newgenex102.htm EXHIBIT 10.2 PROMISSORY NOTE $100,000.00 Titusville, New Jersey, USA October 27, 2016 For value received, Greenwind NRG Inc., a Nevada corporation (?Payee?) agrees to fund, in immediately available funds, within 3 business days of the date hereof, to NewGen BioPharma Corp. (?Maker?) the principal sum of One Hundred Thousand and No/100 Dollars ($100,000) and Maker promises to pay to |
|
| January 11, 2017 |
newgenex21.htm EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG NEWGEN BIOPHARMA CORP. (FORMERLY GREENWIND NRG INC.) and NEWGEN MERGER SUB INC. and NEWGEN BIOPHARMA CORPORATION Dated as of January 10, 2017 1 AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (this ?Agreement?) is made and entered into on January 10, 2017, by and among NEWGEN BIOPHARMA CORP. (formerly GREENWIND NRG |
|
| January 11, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 newgen8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2017 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incor |
|
| November 21, 2016 |
Amended and Restated Bylaws of NewGen BioPharma Corp. grwdex32.htm EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF NEWGEN BIOPHARMA CORP. (FORMERLY GREENWIND NRG INC.) (the ?Corporation?) ARTICLE I: MEETINGS OF SHAREHOLDERS Section 1 - Annual Meetings The annual meeting of the shareholders of the Corporation shall be held at the time fixed, from time to time, by the Corporation?s Board of Directors (each member a ?Director? and collectively, the ?Director |
|
| November 21, 2016 |
grwdex991.htm EXHIBIT 99.1 INFORMATION STATEMENT (INTENDED TO BE DISTRIBUTED TO STOCKHOLDERS ON OR ABOUT NOVEMBER 21, 2016) NEWGEN BIOPHARMA CORP. 3221 Dominquez Avenue Quezon City, Philippines 855-624-4793 Notice of Stockholder Action by Written Consent November 21, 2016 Dear Stockholder: The purpose of this Information Statement is to inform the holders of record, as of the close of business on |
|
| November 21, 2016 |
Certificate of Amendment to Articles of Incorporation dated November 18, 2016. EX-3.1 2 grwdex31.htm CERTIFICATE OF AMENDMENT EXHIBIT 3.1 |
|
| November 21, 2016 |
8-K 1 grwd8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 16, 2016 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incorp |
|
| November 18, 2016 |
grwd8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 18, 2016 NEWGEN BIOPHARMA CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 18, 2016 |
grwdex31.htm EXHIBIT 3.1 7 |
|
| November 2, 2016 |
EX-10.1 2 grwdex101.htm BINDING LETTER OF INTENT EXHIBIT 10.1 BINDING LETTER OF INTENT This Binding Letter of Intent (this “LOI”) is entered into by and between GREENWIND NRG, INC., a Nevada corporation (the “Company” or “Greenwind”), and NEWGEN BIOPHARMA CORP.,a New Jersey corporation (“NewGen”). BACKGROUND AND PURPOSE A. The Company is a fully reporting publicly traded company in good standing o |
|
| November 2, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 27, 2016 GREENWIND NRG INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 19, 2016 |
grwd8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 19, 2016 GREENWIND NRG INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| September 6, 2016 |
Greenwind Nrg FORM 10-Q (Quarterly Report) grwd10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000-1537274 GREENWIND N |
|
| June 14, 2016 |
Greenwind Nrg FORM 10-Q (Quarterly Report) 10-Q 1 2016apr30-grwd10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file |
|
| March 15, 2016 |
Greenwind Nrg FORM 10-Q (Quarterly Report) 10-Q 1 2016jan31-grwd10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission fi |
|
| January 28, 2016 |
GRWD / Greenwind Nrg, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2015 □ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-1537274 GREENWIND NRG INC. (Name of registrant as specified in its charter) Nevada |
|
| September 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000-1537274 GREENWIND NRG INC. |
|
| June 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000-1537274 GREENWIND NRG INC. |
|
| March 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000-1537274 GREENWIND NRG IN |
|
| January 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 greenwind-2014oct3110k.htm FORM-10 K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2014 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-1537274 GREENWIND NRG INC. (Name of re |
|
| September 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000-1537274 GREENWIND NRG INC. |
|
| August 18, 2014 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2014 GREENWIND NRG INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-1537274 N/A (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 18, 2014 |
Silberstein Ungar, PLLC CPAs and Business Advisors EX-16.1 2 ex-161.htm EX-16.1 Silberstein Ungar, PLLC CPAs and Business Advisors Phone (248) 203-0080 Fax (248) 281-0940 30600 Telegraph Road, Suite 2175 Bingham Farms, MI 48025-4586 www.sucpas.com August 15, 2014 Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, DC 205497561 Re: Greenwind NRG, Inc.. We have read the statements included in the 8-K date |
|
| June 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000-1537274 GREENWIND NRG INC. |
|
| March 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period from to Commission file number: 000-1537274 GREENWIND NRG IN |
|
| February 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2013 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-1537274 Greenwind NRG Inc. (Name of registrant as specified in its charter) Nevada |
|
| February 12, 2014 |
Exhibit 21 LIST OF SUBSIDIARIES None. |
|
| January 29, 2014 |
NT 10-K 1 ntform10k.htm NT 10-K SEC FILE NUMBER 000-1537274 CUSIP NUMBER 397029109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b –25 NOTIFICATION OF LATE FILING Check One: xForm 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: October 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Trans |
|
| January 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2014 GREENWIND NRG INC. (Exact Name of Registrant as Specified in its Charter) Nevada 333-178741 N/A (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 11, 2012 |
As Filed With the Securities and Exchange Commission on July 11, 2012 Registration No. |
|
| July 11, 2012 |
Exhibit 10.1 |
|
| July 11, 2012 |
Exhibit 10.3 |
|
| July 11, 2012 |
Exhibit 99.1 SUBSCRIPTION AGREEMENT GREENWING NRG INC. (the "Company") 69 Saphire, The Grange, Stilorgan, Co. Dublin, Ireland Tel: (353) 87 153 6399 A. Instructions. Each person considering subscribing for common shares of the Company should review the following instructions: Subscription Agreement: Please complete, execute and deliver to the Company the enclosed copy of the Subscription Agreement |
|
| July 11, 2012 |
GREENWIND NRG INC. 69 Saphire, The Grange, Stilorgan, Co. Dublin, Ireland Telephone +353 87 153 6399 July 11, 2012 Russell Mancuso Branch Chief SECURITIES AND EXCHANGE COMMISSION 100 F Street, N.E. Washington, D.C. 20549 Re: Greenwind NRG Inc. Registration Statement on Form S-1 Filed June 7, 2012 File No. 333-178741 Dear Mr. Mancuso Thank you for your June 19, 2012 comment correspondence to the ab |
